Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) just unveiled an update.
Shandong Weigao Group Medical Polymer Company Limited reported a 2.6% year-on-year revenue increase for the third quarter, reaching approximately RMB3.26 billion. The orthopedic, interventional, and blood management segments saw significant growth, while pharma packaging and medical devices faced challenges due to pricing pressures from government policies, impacting overall sales revenue growth.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
More about Shandong Weigao Group Medical Polymer Co
Shandong Weigao Group Medical Polymer Company Limited is a joint stock limited company incorporated in the People’s Republic of China. It operates in the medical industry, focusing on products such as orthopedic, interventional, and blood management solutions, as well as pharma packaging and medical devices.
YTD Price Performance: 23.27%
Average Trading Volume: 16,176,271
Technical Sentiment Signal: Sell
Current Market Cap: HK$24.56B
See more insights into 1066 stock on TipRanks’ Stock Analysis page.